EUVIMEDEUVIMED entdecken
Crossref

Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization

Hardik Rana, Ujash Bhalodia, Ayushi Patel, Vaishali Thakkar, Mansi Dholakia, Chetna Modi, Tejal Gandhi

Naunyn-Schmiedeberg's Archives of Pharmacology · 2026

DOI: 10.1007/s00210-025-04747-y ↗

Kurz gefasst

Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Hardik Rana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, Anand Pharmacy College, Anand, India. hardikrana1439@gmail.com. Hauptthemen laut MEDLINE: Thiazines, Lipids, Sulfonamides, Nanoparticles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 65 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A better functional and site-specific drug delivery system for ophthalmic disease is necessary for the treatment of glaucoma. The present study aimed to design a brinzolamide (BRZ)-loaded cubosomal solid lipid nano-vesicular system (Cube-SLNV) that accomplished advanced statistical tools. Another objective was to overcome the problem of burst release associated with Glyceryl monooleate (GMO) Cube-SLNV by incorporating Gelucire 43/01 (GC43/01). The emulsification method was used to synthesize BRZ Cube-SLNV. The Plackett-Burman design (PBD) was utilized to screen the critical material (CMAs) and process attributes (CPPs). The optimization of the Cube-SLNV was accomplished through Box-Behnken design (BBD). Multivariate tools were applied to estimate the correlation between screened CMAs and critical quality attributes (CQAs). The Cube-SLNV was characterized by size, its size distribution, stability, thermal behavior, chemical interactions, BRZ release, entrapment efficiency, pH, sterility testing, and ex vivo irritation study. GMO and GC43/01 were chosen as solid lipids, whereas Poloxamer 407 (PLX) was a stabilizer for Cube-SLNV in preliminary trials. PBD-the Pareto chart suggested the significant influence of the amount of GMO, GC43/01, and PLX on the performance of Cube-SLNV, so chosen as CMAs for further optimization. BBD identified a crucial relationship between chosen CMAs and CQAs - Cube-SLNV size, poly-dispersibility index (PDI), and BRZ release. The optimized Cube-SLNV size was determined to be 101.2 nm, with a zeta potential of - 34.6 mV, a PDI of 0.253, and more than 90% entrapment efficiency. Cube-SLNV can release more than 90% BRZ within 8 h. DSC and FTIR confirmed the formation of Cube-SLNV-loaded BRZ. HATCAM study revealed that the formulation has no irritancy. The controlled release behavior from optimized BRZ with higher entrapment efficiency was observed. Cube-SLNV was developed with the amalgamation of PBD for screening and BBD for correlating CMAs and CQAs. This novel delivery system is a revitalized formulation that promises to give a potential molecule a new lease of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThiazinesLipidsSulfonamidesNanoparticlesCarbonic Anhydrase InhibitorsAnimalsRabbitsDrug LiberationAdministration, OphthalmicParticle SizeMaleDrug Delivery SystemsGlyceridesDrug Carriers

Stichwörter der Autor:innen

Box-Behnken designCubosomesGelucire 43/01Plackett–Burman designPoloxamer 407

Substanzen

brinzolamideThiazinesLipidsSulfonamidesCarbonic Anhydrase InhibitorsGlyceridesDrug Carriersmonoolein

Autor:innen und Institutionen

  • Department of Pharmaceutics, Anand Pharmacy College, Anand, India. hardikrana1439@gmail.com.
  • Department of Pharmaceutics, Anand Pharmacy College, Anand, India.
  • Faculty of Pharmacy, Dharmsinh Desai University, Nadiad, India.

Zitieren

APA

Rana, H., Bhalodia, U., Patel, A., Thakkar, V., Dholakia, M., Modi, C., & Gandhi, T. (2026). Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-025-04747-y

Vancouver

Rana H, Bhalodia U, Patel A, Thakkar V, Dholakia M, Modi C, et al. Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-025-04747-y

BibTeX
@article{Rana2026,
  author = {Rana, Hardik and Bhalodia, Ujash and Patel, Ayushi and Thakkar, Vaishali and Dholakia, Mansi and Modi, Chetna and Gandhi, Tejal},
  title = {Ophthalmic-targeted brinzolamide-laden cubosomal solid lipid nano-vesicular system (Cube-SLNV): design, development, and in vitro and ex vivo characterization},
  journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
  year = {2026},
  doi = {10.1007/s00210-025-04747-y}
}
Kostenlos starten →